170851-70-4
Most orderedIpamorelin
Selective ghrelin receptor agonist pentapeptide with minimal cross-activity.
Typical release99.2%
From
£34.00
In stock
Growth Factor & Secretagogue
CJC-1295 (no DAC)
Modified GRF (1-29) · Mod GRF 1-29 · CJC-1295 without DAC
Tetra-substituted GHRH(1-29) analogue without the drug affinity complex. Short-acting.
Total, ex VAT
£42.00
- Released at ≥ 98.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 863288-34-0
- Molecular formula
- C152H252N44O42
- Average mass
- 3367.9 g/mol
- Residues
- 29
- Class
- GHRH(1-29) analogue
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 98.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- Growth hormone-releasing hormone receptor (GHRHR)
Overview
About CJC-1295 (no DAC)
This is GHRH(1-29) with four substitutions — D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27 — each addressing a specific degradation or aggregation liability in the native sequence. The D-Ala2 substitution is the important one: it blocks DPP-4 cleavage, which otherwise clears native GHRH within minutes.
The 'no DAC' designation matters. CJC-1295 with drug affinity complex carries a maleimide group that binds covalently to serum albumin, extending half-life to days. Without it, the analogue is short-acting, and the two forms behave completely differently in a preparation. They are separate compounds and are frequently confused in secondary sources.
In short
- GHRH(1-29) with four stabilising substitutions including D-Ala2
- No drug affinity complex — short-acting, unlike CJC-1295 with DAC
- Commonly used to study pulsatile rather than sustained GHRHR signalling
- Released at ≥ 98.0% area-percent by RP-HPLC
Where it is used
Research applications
Pulsatile secretion
The short duration of action makes this the analogue of choice where pulsatile GHRHR stimulation is being modelled.
Receptor desensitisation
Comparing short- and long-acting analogues is how desensitisation kinetics at GHRHR are characterised.
Combination studies
Frequently paired with a ghrelin receptor agonist to study the two secretagogue pathways acting together.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of CJC-1295 (no DAC) and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Analogue design
Description of the tetra-substituted GRF analogue and the rationale for each substitution.
Jetté et al., Endocrinology, 2005
GHRH receptor pharmacology
Foundational work on GHRHR signalling and the effect of DPP-4 resistance on analogue duration.
Reviewed in Frohman & Jansson, Endocrine Reviews
Questions
CJC-1295 (no DAC) — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- What is the difference from CJC-1295 with DAC?
- The DAC version carries a maleimide that binds albumin covalently, giving a half-life of days. This version has none and is short-acting. They are different compounds with different masses — check which one a protocol specifies.
- Is Mod GRF 1-29 the same thing?
- Yes. Modified GRF (1-29), Mod GRF 1-29 and CJC-1295 without DAC all denote this tetra-substituted analogue.
- How stable is it in solution?
- 28 days at 2–8 °C. Aliquot if you need repeated withdrawals over that period.
Same class
Others in Growth Factor & Secretagogue
86168-78-7
Sermorelin
The native GHRH(1-29) fragment, unmodified. The reference sequence for GHRH analogue work.
Typical release98.8%From
£52.00
In stock
218949-48-5
Tesamorelin
Full-length GHRH(1-44) with an N-terminal hexenoyl group for protease resistance.
Typical release98.6%From
£114.00
In stock
87616-84-0
GHRP-6
First-generation hexapeptide secretagogue at GHS-R1a, with characteristic off-target endocrine activity.
Typical release99.0%From
£29.00
In stock
Important
CJC-1295 (no DAC) is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.